Abstract
1291P A phase II study of nivolumab rechallenge therapy in advanced NSCLC patients who responded to prior anti-PD-1/L1 inhibitors: West Japan Oncology Group 9616L
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have